One Year Into Kabir Nath̢۪s Leadership, Compass Pathways̢۪ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing -September 19, 2023 at 09:26 am EDT : vimarsana.com

By Faith Ashmore, BenzingaTreatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients....

Related Keywords

Ashmore , Dorset , United Kingdom , San Francisco , California , United States , New York , London , City Of , America , Bristol Meyers Squibb , Kabir Nath , Stephen Schultz , Drug Administration , Company Biocompass Pathways , Nasdaq , Compass Pathways , Access Pathway , Meyers Squibb , Pivotal Trial , Depression Rating Scale , Breakthrough Therapy , Markets ,